Next Article in Journal
A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes
Next Article in Special Issue
From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology
Previous Article in Journal / Special Issue
Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease
Open AccessArticle

A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A

Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland
University of Basel, Petersplatz 1, Basel 4003, Switzerland
Virometix AG, Wagistrasse 14, Schlieren 8952, Switzerland
Department of Chemistry, University of Zürich, Winterthurerstrasse 190, Zürich 8057, Switzerland
Authors to whom correspondence should be addressed.
Academic Editor: Darrell J. Irvine
Vaccines 2015, 3(4), 850-874;
Received: 2 July 2015 / Accepted: 9 October 2015 / Published: 16 October 2015
(This article belongs to the Special Issue Nanoparticle-Based Vaccines)
Alternatives to the well-established capsular polysaccharide-based vaccines against Streptococcus pneumoniae that circumvent limitations arising from limited serotype coverage and the emergence of resistance due to capsule switching (serotype replacement) are being widely pursued. Much attention is now focused on the development of recombinant subunit vaccines based on highly conserved pneumococcal surface proteins and virulence factors. A further step might involve focusing the host humoral immune response onto protective protein epitopes using as immunogens structurally optimized epitope mimetics. One approach to deliver such epitope mimetics to the immune system is through the use of synthetic virus-like particles (SVLPs). SVLPs are made from synthetic coiled-coil lipopeptides that are designed to spontaneously self-assemble into 20–30 nm diameter nanoparticles in aqueous buffer. Multivalent display of epitope mimetics on the surface of SVLPs generates highly immunogenic nanoparticles that elicit strong epitope-specific humoral immune responses without the need for external adjuvants. Here, we set out to demonstrate that this approach can yield vaccine candidates able to elicit a protective immune response, using epitopes derived from the proline-rich region of pneumococcal surface protein A (PspA). These streptococcal SVLP-based vaccine candidates are shown to elicit strong humoral immune responses in mice. Following active immunization and challenge with lethal doses of streptococcus, SVLP-based immunogens are able to elicit significant protection in mice. Furthermore, a mimetic-specific monoclonal antibody is shown to mediate partial protection upon passive immunization. The results show that SVLPs combined with synthetic epitope mimetics may have potential for the development of an effective vaccine against Streptococcus pneumoniae. View Full-Text
Keywords: peptide; streptococcus; synthetic virus-like particle; PspA; vaccine peptide; streptococcus; synthetic virus-like particle; PspA; vaccine
Show Figures

Graphical abstract

MDPI and ACS Style

Tamborrini, M.; Geib, N.; Marrero-Nodarse, A.; Jud, M.; Hauser, J.; Aho, C.; Lamelas, A.; Zuniga, A.; Pluschke, G.; Ghasparian, A.; Robinson, J.A. A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A. Vaccines 2015, 3, 850-874.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop